Resistance Testing and Mechanisms of Resistance in Childhood Leukemia
The prognosis of children with leukemia has improved dramatically due to the development of effective combination chemotherapy. Nevertheless, about 25% of children with acute lymphobalstic leukemia (ALL) and 50% of children with acute myeloid leukemia (AML) die of resistant or relapsed disease. On the other hand, patients who are curable with relatively mild chemotherapy as used in the seventies, will nowadays be overtreated and suffer from unnecessary side-effects. This is due to the fact that therapy has been intensified for all patients in (successful) attempts to cure an increasing number of children.Therefore, it is of the highest importance to identify children with highly sensitive leukemia that can be cured with minimal therapy and children who need specifically intensified therapy. Our research program focusses on the relation between molecular biological characteristics, drug resistance and prognosis in pediatric oncology. Here, results from some recent and currently ongoing studies in leukemia will be described.
KeywordsLeukemia Methotrexate Glucocorticoid Prednisolone Vincristine
Unable to display preview. Download preview PDF.
- 6.Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85:751–756.PubMedGoogle Scholar
- 9.Pieters R, Den Boer ML, Durian M, Janka-Schaub GE, Schmiegelow K, Kaspers GJL, Van Wering ER, Veerman AJR Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia — implications for treatment of infants. Leukemia 1998; 12:1344–1348.PubMedCrossRefGoogle Scholar
- 10.Pieters R, Huismans DR, Loonen AH, Peters GJ, Hählen K, Van der Does-van den Berg A, Van Wering ER, Veerman AJP. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer 1992; 51:213–217.PubMedCrossRefGoogle Scholar
- 12.Pieters R, Huismans DR, Loonen AH, Peters GJ, Hählen K, Van der Does-van den Berg A, Van Wering ER, Veerman AJP. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk Res 1992; 16:873–880.PubMedCrossRefGoogle Scholar
- 13.Den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan ChM, Kaspers GJL, Janka-Schaub GE, Henze G, Creutzig U, Scheper RJ, Veerman AJP. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91:2092–2098.Google Scholar
- 15.Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Van der Does-van den Berg A, Veerman AJP. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92:1–8.Google Scholar